Canadian Cancer Trials Group Bulletins

Trial Management Group


Health Canada Approves Two New IND Trials

IND.227 - A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma received Health Canada Approval on May 20, 2016.

IND. 232 - A Phase II Study of Durvalumab (MEDI4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer received Health Canada Approval on May 26, 2016.

We are looking for more IND sites who would be interested in participating in either of these trials.

If interested please contact Study Coordinator, Caitlin Burns, at cburns@ctg.queensu.ca. It is anticipated that these trials will be centrally activated in late June/early July.